Background-Despite numerous studies demonstrating the efficacy of cellular adoptive transfer for therapeutic myocardial regeneration, problems remain for donated cells with regard to survival, persistence, engraftment, and long-term benefits. This study redresses these concerns by enhancing the regenerative potential of adoptively transferred cardiac progenitor cells (CPCs) via genetic engineering to overexpress Pim-1, a cardioprotective kinase that enhances cell survival and proliferation. Methods and Results-Intramyocardial injections of CPCs overexpressing Pim-1 were given to infarcted female mice.
S
tem cell-based interventional approaches for myocardial regeneration have recently generated substantial enthusiasm as a novel treatment for heart failure. Despite initial optimism, application of regenerative medicine in the myocardium has been stymied by the marginal regenerative potential of adoptively transferred stem cell populations. Experimental studies routinely find that the vast majority of adoptively transferred stem cells die or vanish shortly after delivery. Thus, the benefits observed are likely mediated by a small population of surviving cells, leading to the postulate that improving cardiac progenitor cell (CPC) survival and proliferation will have dramatic consequences for enhancing myogenesis and will empower therapeutically relevant implementation of myocardial regeneration.
Clinical Perspective on p 2087
CPCs expressing the stem cell marker c-kit ϩ reside within the heart, 1,2 mediating the maintenance and repair of damaged cardiac tissue in response to myocardial injury. 1, [3] [4] [5] [6] CPCs have been isolated and used with modest success for the treatment and regeneration of damaged heart tissue after infarction. 4, [7] [8] [9] Ideally, to enhance the regenerative process, adoptively transferred CPCs would benefit from modification to promote cellular survival and proliferation without inhibiting lineage commitment and differentiation provided by appropriate environmental cues.
Previous studies by our group have identified Pim-1, a kinase responsible for cardioprotection downstream of Akt signaling 10 that is a conserved serine/threonine protein kinase originally described as the proviral integration site of the Moloney murine leukemia virus. 11 Primary downstream targets of Pim-1 include molecules responsible for the regulation of cellular survival and mitotic activity. [11] [12] [13] [14] [15] The role of Pim-1 in promoting proliferation and transition through the cell cycle has been documented extensively. [15] [16] [17] [18] [19] Unlike native Akt regulated by phosphorylation, Pim-1 is constitutively activated and is produced in response to stress or pathological injury in the myocardium. Pim-1 is also expressed in activated stem cells 20 and in endothelial 21 and vascular smooth muscle cells. 14 Although the cardioprotec-tive effects of Pim-1 are clear from our work, 10, 22 the impact of Pim-1 as a mediator of myocardial regeneration remains to be explored. Results presented here demonstrate the beneficial capacity of Pim-1 to enhance cardiac regeneration, advancing the concept of ex vivo gene therapy with cultured CPCs to enhance cardiogenesis when reintroduced into infarcted myocardium.
Methods

Generation of Lentiviral Vectors
CPCs were genetically modified through the use of a bicistronic lentiviral vector to deliver the human Pim-1 gene under control of a myeloproliferative sarcoma virus LTR-negative control region deleted (MND) promoter and enhanced green fluorescence protein (eGFP) driven off a vIRES. Lentivirus was made as previously described. 23 
Cardiac Progenitor Cell Isolation, Culture, and Transductions
CPCs were isolated from syngenic male FVB mice as previously described 5 and cultured for 3 weeks in cardiac stem cell media. CPCs were plated (0.2ϫ10 6 cells per well) in 48-well plates, transduced with lentivirus (multiplicity of infectionϭ10) with 4 g/mL polybrene, expanded, and analyzed by flow cytometry to determine the percentage of eGFP ϩ cells. CPCs were differentiated as previously described 5 
with 10
Ϫ8 mol/L dexamethasone.
Superarrays
messenger RNA and complementary DNA from CPC populations modified with lentiviral vectors expressing eGFP (Lv-egfp) (CPCe) and in combination with Pim-1 kinase (Lv-egfpϩPim1) (CPCeP) were obtained with Triazol (Invitrogen, Carlsbad, Calif) and harvested per the manufacturer's protocol. Apoptosis (PAMM-012) and cell proliferation (APMM-012) arrays were obtained from SuperArray (Frederick, Md) and were run according to the manufacturer's protocol.
Trypan Blue Exclusion and MTT Assay
Uninfected CPCs, CPCe, and CPCeP were plated in quadruplicate (10 000 cells per well) in 24-well plates. Viable cells were determined by trypan blue exclusion. For the MTT assay, 5000 cells per well were plated in 96-well plates, incubated 4 to 5 hours with 50 g MTT reagent (Fluka, Sigma, St Louis, Mo), treated with 100 L stopping reagent (0.01N HCl plus 10% SDS) overnight at 37°C, and analyzed on a spectrophotometer at 570 nm. Quercetagetin (No. 551590, Calbiochem, San Diego, Calif) was incubated with cells at 10 mol/L when indicated.
Myocardial Infarction, Injections, Echocardiography, and Hemodynamics
Infarctions, echocardiography, and hemodynamics were performed as previously described, 10 Additional details are given in the onlineonly Data Supplement.
Confocal Microscopy
Heart sections were deparaffinized, and antigen was retrieved in 1 mmol/L citrate (pH 6.0), followed by a 1-hour block in TNB (Perkin Elmer, Woodbridge, Ontario). Primary antibodies were incubated overnight at 4°C at appropriate dilutions (see the Methods section in the online-only Data Supplement). Slides were washed in 1ϫ Tris/NaC1 followed by secondary antibody incubation for 2 hours at room temperature. Subsequent tyramide amplification was performed as necessary.
Telomere Length
Paraffin sections were prepared for in situ hybridization and stained for telomere length as per manufacturer's protocol (Dako, Glostrup, Denmark).
Animal Studies
All animal studies were approved by Institutional Animal Care and Use Committee.
Statistics
Statistics were calculated with SPSS software (SPSS Inc, Chicago, Ill). One-way ANOVA and 2-way repeated-measures ANOVA for echocardiography with the Tukey posthoc test were calculated. Values of PϽ0.05 were considered statistically significant. Generalized estimating equations with empirical (robust) covariance estimation were used to confirm 2-way ANOVA results.
Results
Pim-1 Lentiviral Vector Expression in CPCs
Bicistronic Lv-egfp or Lv-egfpϩPim1 ( Figure IA of the online-only Data Supplement) was used to introduce complementary DNA constructs into c-kit ϩ CPCs isolated from male nontransgenic FVB mice. CPCe or CPCeP were subjected to immunoblot analyses to confirm protein expression of genomically integrated gene products. eGFP protein expression was present in CPCe and CPCeP, and increased protein levels for Pim-1 was present in CPCeP samples ( Figure IB of the online-only Data Supplement). CPCs and CPCe showed low-level endogenous Pim-1 protein expression.
Pim-1 Increases CPC Proliferation
CPCeP exhibit increased proliferation compared with CPCe (PϽ0.05) and CPCs (PϽ0.001) as assessed by trypan blue exclusion ( Figure 1A ). In comparison, increased CPCe cell numbers observed at day 4 were not maintained at day 6. CPCeP also possess increased metabolic rates relative to CPCe at time 0 (PϽ0.001) or at 48 hours (PϽ0.001) in vitro as determined by MTT assay ( Figure 1B ). The increase in CPCeP growth rate was abrogated by addition of Quercetagetin (a specific Pim-1 activity inhibitor) after 48 and 72 hours (PϽ0.001) relative to vehicle-treated CPCeP ( Figure  1C ). Several messenger RNAs encoded by genes responsible for cell cycle arrest are downregulated in CPCeP by array analysis ( Figure II of the online-only Data Supplement). Immunoblot analyses of CPCeP also show decreased expression of p27, a cell cycle-dependent kinase inhibitor ( Figure  1D ). Thus, enhanced proliferation of CPCeP is likely due to altered regulation of cell cycle inhibitors. 
CPCeP Differentiate Into Cardiac, Endothelial, and Smooth Muscle Lineages
CPCeP Improve Cardiac Function 12 Weeks After Myocardial Infarction
Transgenic mice with cardiac-specific Pim-1 expression are resistant to infarction challenge 10, 22 ; therefore, CPCeP should ameliorate pathological damage after adoptive transfer into infarcted myocardium. Twelve-week-old female mice subjected to myocardial infarction were treated with CPCe or CPCeP injected directly into the peri-ischemic border zone. Hearts of mice receiving CPCeP possessed thicker anterior wall dimension compared with vehicle-(PϽ0.001) or CPCe-(PϽ0.01) injected mice ( Figure 3A ) by echocardiography at 2 weeks. Both groups receiving CPCs showed significant improvements in ejection fraction (EF) and fractional shortening (FS) at 4 weeks after delivery (PϽ0.05) relative to vehicle-injected mice (PϽ0.05; Figure 3B Mice receiving CPCeP injections were compared with mice receiving CPCe injections over an extended 12-week time course after delivery into infarcted hearts to assess long-lasting beneficial effects. Injection of CPCe conferred improved function at 1 week after delivery but transitioned into decompensation at 6 weeks, becoming indistinguishable from vehicle controls by 8 weeks ( Figure 3B and 3C). In comparison, CPCeP-injected mice maintained EF and FS and had significantly improved function relative to CPCe-injected mice at 6 weeks after delivery. At 12 weeks, CPCeP treatment preserved EF and FS, whereas CPCe-treated hearts suffered from a 2-fold and 1.6-fold decrease in function, respectively ( Figure 3B and 3C) . Significantly enhanced cardiac function in mice receiving CPCeP was confirmed by measurement of left ventricular developed pressure, left ventricular end-diastolic pressure, and changes in dP/dt and ϪdP/dt ( Figure 3D through 3F) relative to mice receiving CPCe.
Injection of CPCeP Leads to Infarct Reduction, De Novo Myocyte Formation, and Neovascularization
Hearts from CPCe-and CPCeP-injected animals were immunostained with sarcomeric tropomyosin to detect surviving myocardium at 12 weeks after infarction. CPCeP-injected hearts showed significant reductions in infarct size (1.5-fold; 
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PϽ0.05; Figure 4A ) and fibrosis ( Figure VI of the onlineonly Data Supplement) relative to CPCe-treated hearts. In CPCeP-injected hearts 39.8% of the surviving myocardium within the infarct was eGFP ϩ ( Figure 4B ). This corresponded to a significant (PϽ0.001) 4-fold increase compared with CPCe-injected hearts.
Persistence and cellular phenotype of donated CPCs were examined at 12 weeks after delivery by immunostaining of myocardial sections with antibodies to eGFP colocalized with sarcomeric tropomyosin to detect myocytes and with connexin-43, suggesting formation of functional gap junctions with neighboring cells ( Figure 4C ). Coincident localization of eGFP and striated tropomyosin labeling is indicative of myocytes presumptively derived from the donated cell population in hearts receiving CPCeP. Interestingly, although de novo myocardium is formed in the central area of the infarcted region, the majority of regeneration from transplanted cells is at or adjacent to the border zone where cells are initially injected. A donor-derived origin for these eGFP Together with myocyte labeling, vessels coincident with eGFP were observed by colocalization with antibodies to vWF ( Figure 4D ) or smooth muscle actin ( Figure 4E ) from vehicle-treated and CPCe-and CPCeP-injected hearts 12 weeks after infarction. Quantitative assessment of lineage markers demonstrated that in CPCeP-injected hearts, 32.8% and 51.6% of the eGFP ϩ population stained positive for vWF and smooth muscle actin ( Figure 4F ), respectively. This correlated to a significant 1.8-and 2.3-fold increase compared with CPCe, further implicating the CPCeP population in the formation of new vasculature.
Increased Numbers of c-kit ؉ Cells in Hearts Receiving CPCeP Show Enhanced Proliferation
The presence of c-kit ϩ cells within the infarct area was quantified to assess enhanced recruitment of endogenous stem cells by CPCeP. 6, 9, 24 CPCeP-treated hearts had a 2.6-fold increase in total c-kit cells relative to CPCe at 12 weeks ( Figure 5A and 5B). Quantification of the number of eGFP ϩ c-kit ϩ cells in CPCeP-injected hearts demonstrated that CPCeP had a 6-fold increase compared with CPCe ( Figure  5C ). The number of eGFP Ϫ c-kit ϩ cells was not statistically different between CPCeP and CPCe ( Figure 5D ). Furthermore, CPCeP have increased proliferation in vivo as determined by quantification of BrdU incorporation at 5 weeks and by proliferating cell nuclear antigen immunolabeling at 12 weeks after delivery (see the Results section and Figure  VIIIA and VIIIB of the online-only Data Supplement). Hearts receiving CPCeP also showed decreased apoptotic cell death in resident myocardium (see the Results section and Figure  VIIIC of the online-only Data Supplement). Collectively, these results indicate CPCeP have an increased ability to survive and proliferate in the damaged myocardium compared with CPCe.
Persistent Improvement in Myocardial Performance Is Afforded by CPCeP
The beneficial effects of adoptively transferred cell populations are often measured within days or a few weeks after delivery, 6,9,25,26 but genetic modification of CPCs with Pim-1 may allow long-term functional improvements not observed with normal cells. A 32-week longitudinal study was performed to determine myocardial function in infarcted mice receiving vehicle, CPCe, or CPCeP. Validity of the infarction was verified at 3 days by statistically equivalent decreases in EF, FS, and anterior wall dimension ( Figure 6A through 6C) of all 3 infarcted experimental groups. CPCeP-injected mice showed improved FS and EF by 1 week after delivery, which was sustained throughout the course of the study ( Figure 6A and 6B). CPCeP-injected hearts also had significantly increased anterior wall dimension relative to CPCe-injected hearts at 32 weeks ( Figure 6C ). In vivo hemodynamic analysis confirmed improved myocardial performance after CPCeP treatment, evidenced by decreased left ventricular end-diastolic pressure, increased developed pressure, dP/dt, and ϪdP/dt ( Figure 6D through 6F) , relative to mice receiving CPCe. Ratios of heart weight to body weight in CPCePtreated mice were comparable to those in sham-operated controls and significantly smaller relative to CPCe-and vehicle-injected controls (PϽ0.05; Figure 6G ). Cardiac remodeling as determined by the law of Laplace revealed that the ratio of left ventricular diameter (r) to wall thickness (h) was significantly decreased in mice receiving CPCeP at 36 weeks after delivery ( Figure 6H) . Results from the 32-week time course validate results obtained in the 12-week study ( Figure 3 ) and demonstrate persistent and significant im- provement in myocardial performance and remodeling afforded only by CPCeP.
CPCeP Engraftment and Commitment Persists Up to 32 Weeks After Intramyocardial Injection
Myocardial samples from mice receiving CPCe and CPCeP were examined for the presence of adoptively transferred cells as evidenced by the presence of immunoreactivity for eGFP coincident with markers of cardiogenic lineages at 32 weeks after delivery. Myocytes expressing eGFP were detected in hearts receiving either CPCe or CPCeP. Similar to observations at 12 weeks ( Figure 4A ), hearts receiving CPCeP showed a significant 1.3-fold reduction in infarct size ( Figure 7A ). In CPCeP-injected hearts, 32.8% of the surviving myocardium was eGFP ϩ (Figure 7B and 7C) . This corresponded to a significant (PϽ0.001) 6-fold increase compared with CPCe-injected hearts. CPCeP-injected animals also had significant increases in total c-kit ϩ cells (2.9-fold) at 32 weeks relative to CPCe-injected hearts. CPCeP-injected hearts had a significant 7.9-fold increase in the number of eGFP ϩ c-kit ϩ cells compared with CPCe, whereas the number of eGFP Ϫ c-kit ϩ cells was not statistically different between the 2 groups ( Figure 7D through 7G) . Hearts of mice receiving CPCeP showed a 71% increase in vascular density in the infarct region visualized by immunostaining for smooth muscle actin, with 74% more vessels characterized by a small diameter of 1 to 2 cells evident in the circumference ( Figure 7H through 7J) .
Discussion
A revolution in the treatment of heart disease has begun, initiated by the discovery of stem cell-mediated myocardial regeneration. 2, 27, 28 As the field matures, key observations and recurrent themes continue to emerge from experimental and clinical studies: (1) Myocardial structure and function are consistently and reproducibly improved, although the degree of benefit is modest; (2) the vast majority of adoptively transferred stem cells are lost as a result of death or poor retention after delivery; (3) long-term efficacy of the regenerative process mediated by adoptively transferred cells remains debatable, in part because of their short-lived nature; (4) therapeutically relevant implementation of stem cellbased myocardial repair ultimately depends on enhancing the modest regenerative effects currently observed; and (5) ex vivo modification or treatment of adoptively transferred stem cells significantly enhances reparative and regenerative processes. The first 4 observations point out that present-day stem cell-based myogenesis and regeneration approaches fall short of the efficacy desired for reconstitution of myocardial tissue after cardiomyopathic injury. However, point 5 offers hope in the form of engineering stem cells to enhance their regenerative capacity.
Several laboratories have demonstrated impressive gains in blunting infarction damage through the use of stem cells modified by genetic engineering 29 -32 or exposure to environmental, chemical, and biological treatments before delivery. 29, [33] [34] [35] A consistent theme from these studies is that the ex vivo manipulation of the stem cell population has salutary effects for the adoptively transferred cells and for the host myocardium on reintroduction. The mechanistic basis of these treatments has been linked to enhanced cellular survival, secretion of paracrine factors, activation of endogenous repair processes, and contribution of the donated cells to the formation of de novo myocardium. Among studies of ex vivo stem cell modification, activation of survival kinases such as Akt is an effective strategy for potentiating stem cell regeneration, but severely limited or a complete lack of direct participation in de novo tissue formation and marginal longterm engraftment of engineered cells remain serious limitations. 31,34,36 -39 Downstream of nuclear Akt signaling, we identified Pim-1 10 kinase, which stabilizes proproliferative proteins and influences their subcellular localization through phosphorylation and/or direct association. Examples include nuclear export and subsequent degradation of the cyclindependent kinase inhibitors p27 and p21, 18, 19 stabilization of c-myc, 15 and mitotic complex assembly with nuclear mitotic apparatus. 16 Additionally, CPCs from Pim-1 transgenic mice show elevated levels of nucleostemin, a protein with an expression that is associated with maintenance of proliferation in stem cells. 40 Consistent with the role of Pim-1 in increased proliferation, our studies demonstrate that injection of CPCeP promotes increased density of eGFP ϩ c-kit ϩ cells in the region of infarction (Figures 5B and 7B ). In addition, antiapoptotic 41, 42 and proproliferative 11 actions of Pim-1 were observed with CPCs in vitro (Figure 1 and Figure II Figure  4F ). Pim-1 is also necessary for vascular smooth muscle cell proliferation, whereas knockdown inhibited capillary formation and reduced vascular smooth muscle cell proliferation. 14 These results imply that CPCeP may be predisposed toward ϩ (E), and eGFP Ϫ (F) c-kit ϩ cells in heart sections from mice treated with CPCe (nϭ3) or CPCeP (nϭ3) 32 weeks after infarction. G, Immunolabeling with eGFP (green), c-kit (red), tropomyosin (blue), and nuclear stain Topro-3-iodide (white). Quantification of total number of vessels (H), small vessels (I), and immunolabeling for vasculature (J) in hearts from mice treated with CPCe (nϭ3) or CPCeP (nϭ3) 32 weeks after infarction. Sections were stained with eGFP (green), smooth muscle actin (red), tropomyosin (blue), and nuclear stain Topro-3-iodide (white). MeanϮSEM; nϭ3. Scale barsϭ50 m. LV indicates left ventricular. *PϽ0.05; **PϽ0.01; ***PϽ0.001. Autologous stem cell therapy suffers from critical limitations in cellular survival and persistence that may be amenable to ex vivo genetic modification for regenerative therapy. However, lentiviral modification allowing chromosomal integration and long-term persistence also poses regulatory and safety concerns. Although oncogenic transformation has not been observed with CPCeP, safe and efficacious viral modification of CPCs may require inducible Pim-1 expression. Taken together, our data suggest that Pim-1-mediated CPC reprogramming provides profound improvements in cardiac structure and function that may prove to be superior to current treatment modalities. The long-term goal is to advance these findings toward translational therapeutic implementation of ex vivo gene therapy to enhance stem cell-based cardiac myogenesis.
